Table 1 Patient demographics and clinical charateristics
Characteristic | Total (n = 200) | HPVA (n = 185) | NHPVA (n = 15) | Pa |
|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | ||
Age | Â | Â | Â | 0.014 |
 ≤ 37 | 34 (17.0%) | 28 (82.4%) | 6 (17.6%) |  |
 > 37 | 166 (83.0%) | 157 (94.6%) | 9 (5.4%) |  |
HPV DNA |  |  |  |  < 0.001 |
 Negative (0–1 pg/ml) | 34 (17.0%) | 26 (76.5%) | 8 (23.5%) |  |
 Positive (≥ 1 pg/ml) | 110 (55.0%) | 108 (98.2%) | 2 (1.8%) |  |
 Not avaiable | 56 (28.0%) | 51 (51.8%) | 5 (4.2%) |  |
HPV genotype | Â | Â | Â | 0.273 |
 HPV 16 | 49 (24.5%) | 47 (95.9%) | 2 (4.1%) |  |
 HPV 18 | 60 (30.0%) | 57 (95.5%) | 3 (5.0%) |  |
 Other | 11 (5.5%) | 11 (100.0%) | 0 (0.0%) |  |
 Negative | 72 (36.0%) | 63 (87.5%) | 9 (12.5%) |  |
 Not avaiable | 8 (4%) | 7 (87.5%) | 1 (12.5%) |  |
HPV RNAscope | Â | Â | Â | 0.003 |
 ≤ 3.3 | 99 (49.5%) | 86 (46.5%) | 13 (13.1%) |  |
 > 3.3 | 101 (50.5%) | 99 (98.0%) | 2 (2.0%) |  |
Tumor size (cm) | Â | Â | Â | 0.004 |
 ≤ 4.5 | 178 (89.0%) | 168 (94.4%) | 10 (5.6%) |  |
 > 4.5 | 22 (11.0%) | 17 (77.3%) | 5 (22.7%) |  |
FIGO stage |  |  |  |  < 0.001 |
 I | 141 (70.5%) | 137 (97.2%) | 4 (2.8%) |  |
 II | 51 (25.5%) | 43 (84.3%) | 8 (15.7%) |  |
 III | 5 (2.5%) | 4 (80.0%) | 1 (20.0%) |  |
 IV | 3 (1.5%) | 1 (33.3%) | 2 (66.7%) |  |
Differentiation | Â | Â | Â | 0.537 |
 Good | 10 (5.0%) | 7 (70.0%) | 3 (30.0%) |  |
 Moderate | 106 (53.0%) | 96 (90.6%) | 10 (9.4%) |  |
 Poor | 84 (42.0%) | 82 (97.6%) | 2 (2.4%) |  |
LVI | Â | Â | Â | 0.141 |
 None (0) | 138 (69.0%) | 130 (94.2%) | 8 (5.8%) |  |
 Focal (1–4) | 37 (18.5%) | 31 (83.8%) | 6 (16.2%) |  |
 Moderate (5–9) | 15 (7.5%) | 14 (93.3%) | 1 (6.7%) |  |
 Extensive (≥ 10) | 10 (66.7%) | 10 (100.0%) | 0 (0.0%) |  |
Invasion level of uterine cervix | Â | Â | Â | 0.008 |
 < 1/3 | 54 (27.0%) | 53 (98.1%) | 1 (1.9%) |  |
 1/3–2/3 | 61 (31.0%) | 60 (96.8%) | 2 (3.2%) |  |
 ≥ 2/3 | 84 (42.0%) | 72 (85.7%) | 12 (14.3%) |  |
Lymph nodes invasion | Â | Â | Â | 0.024 |
 No | 154 (77.0%) | 146 (94.8%) | 8 (5.2%) |  |
 Yes | 46 (23.0%) | 39 (84.8%) | 7 (46.7%) |  |
Parametrium invasion | Â | Â | Â | 0.599 |
 No | 181 (90.5%) | 168 (92.8%) | 13 (7.2%) |  |
 Yes | 19 (9.5%) | 17 (89.5%) | 2 (10.5%) |  |
Surgical margin |  |  |  |  < 0.001 |
 No | 187 (93.5%) | 177 (94.7%) | 10 (5.3%) |  |
 Yes | 13 (6.5%) | 8 (61.5%) | 5 (38.5%) |  |
Treatment | Â | Â | Â | 0.235 |
 Surgery | 83 (41.5%) | 80 (96.4%) | 3 (3.6%) |  |
 Surgery + chemotherapy | 21 (10.5%) | 20 (95.2%) | 1 (4.8%) |  |
 Surgery + radiotherapy | 41 (20.5%) | 36 (87.8%) | 5 (12.2%) |  |
 Surgery + chemoradiation | 55 (27.5%) | 49 (89.1%) | 6 (10.9%) |  |
MMR status | Â | Â | Â | 0.978 |
 dMMR | 13 (6.5%) | 12 (92.3%) | 1 (7.7%) |  |
 pMMR | 187 (93.5%) | 173 (92.5%) | 14 (7.5%) |  |
P16 IHC | Â | Â | Â | 0.001 |
 Negative | 82 (41.0%) | 70 (85.4%) | 12 (14.6%) |  |
 Positive | 118 (59.0%) | 115 (97.5%) | 3 (2.5%) |  |
Ki-67 IHC | Â | Â | Â | 0.131 |
 ≤ 12.5% | 48 (24%) | 42 (87.5%) | 6 (12.5%) |  |
 > 12.5% | 152 (76%) | 143 (94.1%) | 9 (5.9%) |  |